Literature DB >> 7835942

Influence of mouse genotype and bacterial virulence in the generation of interferon-gamma-producing cells during the early phase of Salmonella typhimurium infection.

N Benbernou1, C Nauciel.   

Abstract

Interferon-gamma (IFN-gamma) is known to play a major role in resistance to Salmonella typhimurium infection. In this study, the IFN-gamma production in spleens of mice infected with S. typhimurium was analysed at the single cell level using an ELISPOT method. The in vivo IFN-gamma production during the early phase of infection with virulent and avirulent S. typhimurium strains was examined in four mouse strains. Data show that infection with a virulent strain of S. typhimurium caused a much greater enhancement in the frequency of IFN-gamma-producing cells in innately resistant (ltyr) mice (CBA and DBA/2) than in susceptible (ltys) mice (C57BL/6 and BALB/c). In contrast, infection with an avirulent strain of S. typhimurium induced a clear increase in the number of IFN-gamma-producing cells in susceptible mice which was even greater than in resistant ones. These results indicate that both the host genetic background and bacterial virulence play a critical role in the regulation of IFN-gamma production during the early phase of S. typhimurium infection.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7835942      PMCID: PMC1414948     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  31 in total

1.  Murine cutaneous leishmaniasis: resistance correlates with the capacity to generate interferon-gamma in response to Leishmania antigens in vitro.

Authors:  M D Sadick; R M Locksley; C Tubbs; H V Raff
Journal:  J Immunol       Date:  1986-01       Impact factor: 5.422

2.  One-signal requirement for interferon-gamma production by human large granular lymphocytes.

Authors:  H A Young; J R Ortaldo
Journal:  J Immunol       Date:  1987-08-01       Impact factor: 5.422

3.  A T cell-independent mechanism of macrophage activation by interferon-gamma.

Authors:  G J Bancroft; R D Schreiber; G C Bosma; M J Bosma; E R Unanue
Journal:  J Immunol       Date:  1987-08-15       Impact factor: 5.422

4.  Monoclonal antibodies against murine gamma interferon.

Authors:  M Prat; G Gribaudo; P M Comoglio; G Cavallo; S Landolfo
Journal:  Proc Natl Acad Sci U S A       Date:  1984-07       Impact factor: 11.205

5.  Immune interferon induced by phytohemagglutinin in nude mouse spleen cells.

Authors:  J Wietzerbin; S Stefanos; R Falcoff; M Lucero; L Catinot; E Falcoff
Journal:  Infect Immun       Date:  1978-09       Impact factor: 3.441

6.  Role of T cells, TNF alpha and IFN gamma in recall of immunity to oral challenge with virulent salmonellae in mice vaccinated with live attenuated aro- Salmonella vaccines.

Authors:  P Mastroeni; B Villarreal-Ramos; C E Hormaeche
Journal:  Microb Pathog       Date:  1992-12       Impact factor: 3.738

7.  Genetic control of the innate resistance of mice to Salmonella typhimurium: expression of the Ity gene in peritoneal and splenic macrophages isolated in vitro.

Authors:  C R Lissner; R N Swanson; A D O'Brien
Journal:  J Immunol       Date:  1983-12       Impact factor: 5.422

8.  Requirement of endogenous interferon-gamma production for resolution of Listeria monocytogenes infection.

Authors:  N A Buchmeier; R D Schreiber
Journal:  Proc Natl Acad Sci U S A       Date:  1985-11       Impact factor: 11.205

9.  Monoclonal antibody to murine gamma interferon inhibits lymphokine-induced antiviral and macrophage tumoricidal activities.

Authors:  G L Spitalny; E A Havell
Journal:  J Exp Med       Date:  1984-05-01       Impact factor: 14.307

10.  Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity.

Authors:  C F Nathan; H W Murray; M E Wiebe; B Y Rubin
Journal:  J Exp Med       Date:  1983-09-01       Impact factor: 14.307

View more
  8 in total

1.  Clonal expansion of antigen-specific CD4 T cells following infection with Salmonella typhimurium is similar in susceptible (Itys) and resistant (Ityr) BALB/c mice.

Authors:  Z M Chen; M K Jenkins
Journal:  Infect Immun       Date:  1999-04       Impact factor: 3.441

2.  The full expression of the ity phenotype in ityr mice requires C3 activation by Salmonella lipopolysaccharide.

Authors:  F Nishikawa; S Yoshikawa; H Harada; M Kita; E Kita
Journal:  Immunology       Date:  1998-12       Impact factor: 7.397

3.  Interferon-gamma plays a critical role in intestinal immunity against Salmonella typhimurium infection.

Authors:  S Bao; K W Beagley; M P France; J Shen; A J Husband
Journal:  Immunology       Date:  2000-03       Impact factor: 7.397

4.  Systemic infection of mice by wild-type but not Spv- Salmonella typhimurium is enhanced by neutralization of gamma interferon and tumor necrosis factor alpha.

Authors:  P A Gulig; T J Doyle; M J Clare-Salzler; R L Maiese; H Matsui
Journal:  Infect Immun       Date:  1997-12       Impact factor: 3.441

5.  Differential induction of carrier antigen-specific immunity by Salmonella typhimurium live-vaccine strains after single mucosal or intravenous immunization of BALB/c mice.

Authors:  K L Karem; S Chatfield; N Kuklin; B T Rouse
Journal:  Infect Immun       Date:  1995-12       Impact factor: 3.441

6.  Gamma interferon and interleukin-10 gene expression in innately susceptible and resistant mice during the early phase of Salmonella typhimurium infection.

Authors:  S Pie; P Matsiota-Bernard; P Truffa-Bachi; C Nauciel
Journal:  Infect Immun       Date:  1996-03       Impact factor: 3.441

7.  Effect of interleukin 12 neutralization on host resistance and gamma interferon production in mouse typhoid.

Authors:  P Mastroeni; J A Harrison; J A Chabalgoity; C E Hormaeche
Journal:  Infect Immun       Date:  1996-01       Impact factor: 3.441

8.  Salmonella typhimurium persists within macrophages in the mesenteric lymph nodes of chronically infected Nramp1+/+ mice and can be reactivated by IFNgamma neutralization.

Authors:  Denise M Monack; Donna M Bouley; Stanley Falkow
Journal:  J Exp Med       Date:  2004-01-19       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.